OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Share this article This latest deal will aid BMS in bolstering its neuroscience portfolio. Credit: Katherine Welles / Shutterstock.com. Bristol Myers Squibb (BMS) has concluded

March 19, 2024

Canadian LP Bargains

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

September 19, 2024

WHO announces €1.1bn collaboration to eradicate polio – Pharmaceutical Technology

The partnership aims to eradicate polio once and for all. Credit: THOM LEACH / SCIENCE PHOTO LIBRARY via Getty Images. The European Commission, the European

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.